Davide Capodanno/LinkedIn
Jan 11, 2026, 03:54
DAPT De-escalation After PCI․ Where Do We Stand Today?
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared on X:
“ DAPT after PCI remains essential, but balancing ischemic protection and bleeding risk is challenging. Over the past decade, trials have supported DAPT de-escalation—via dose reduction, drug withdrawal, or switching agents—to reduce bleeding without compromising ischemic outcomes in selected patients. Evidence for escalation is more limited. We wrote this review to summarize current data and ongoing studies. ”
Title: Dual Antiplatelet Therapy Escalation and De-escalation
Authors: Antonio Greco, Giacinto Di Leo, Simone Finocchiaro, Antonino Imbesi, Davide Capodanno
Read full article here.
Stay updated with Hemostasis Today.
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly
-
May 28, 2026, 04:29Samone Cook: When Collaboration Turns Into Organizational Coagulation
-
May 28, 2026, 03:42Lara Bloom: 15,000 Steps, Countless Conversations – One Unforgettable WHA79
-
May 27, 2026, 23:00Octavio Marques Pontes-Neto: Exchanging Latin American Experiences at the Global Stroke Alliance Meeting in Buenos Aires
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?